Bristol Myers' psoriasis drug beats Amgen rival in phase 3

Bristol Myers' psoriasis drug beats Amgen rival in phase 3

Source: 
Fierce Biotech
snippet: 

Bristol Myers Squibb’s deucravacitinib has outperformed Amgen’s Otezla in a phase 3 clinical trial of patients with moderate to severe plaque psoriasis. The study linked deucravacitinib to improvements in symptom severity against two measures that served as the co-primary endpoints.